BioDelivery Sciences International, Inc. BDSI is scheduled to report first-quarter 2019 results on May 6 after market close.
Shares of the company have increased 27.5% so far this year compared with the industry’s rise of 4%.
BioDelivery’s earnings performance has been encouraging over the trailing four quarters. While the company surpassed expectations in three of the last four quarters, it matched the same once, delivering an average positive surprise of 16.53%.
In the last reported quarter, the company’s earnings were in line with the Zacks Consensus Estimate.
Let’s see how things are shaping up prior to this announcement.
Factors at Play
Belbuca (chronic pain) and Bunavail (opioid-dependence) constitute BioDelivery’s marketed portfolio. The company is also reviewing strategic option to re-launch Onsolis.
We expect Belbuca to maintain its sales growth momentum and the drug to drive BioDelivery’s total sales in the first quarter. The company witnessed consistent increase in new patients as well as in total prescription of this drug in every quarter of 2018.
The company significantly improved managed care coverage for the drug and also expanded its sales force to support the growth. In February, the company secured preferred coverage by Cigna Healthcare, a leading U.S. pharmacy benefit manager. With this new coverage, Belbuca’s preferred access expands to more than 115 million patients. This increased coverage is expected to boost Belbuca’s sales in the first quarter. We remind investors that the company re-acquired worldwide rights to Belbuca in early 2017 from Endo International Plc ENDP.
Bunavail sales declined in the past couple of quarters and we expect this negative trend to be reflected in the soon-to-be reported quarter’s results as well.
Research and development expenses have been declining over the past three years and the decline is expected to continue in the soon-to-be reported quarter. Meanwhile, the expansion of sales force for Belbuca is likely to increase selling, general and administrative expenses.
Investor focus will be on initiatives to boost the prospects of Bunavail and re-launch of Onsolis on the first-quarter earnings call.
Our proven model does not conclusively show that BioDelivery is likely to beat estimates this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to be able to beat estimates. But that is not the case here, as you will see below.
Earnings ESP: BioDelivery’s Earnings ESP is 0.00%. This is because both the Most Accurate Estimate and the Zacks Consensus Estimate stand at earnings of 10 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: BioDelivery’s Zacks Rank #3 increases the predictive power of ESP. However, we need to have a positive ESP to be confident about an earnings surprise.
Note that we caution against stocks with a Zacks Rank #4 (Sell) or 5 (Strong Sell) going into an earnings announcement, especially when the company is seeing negative estimate revisions.
BioDelivery Sciences International, Inc. Price and Consensus
BioDelivery Sciences International, Inc. Price and Consensus | BioDelivery Sciences International, Inc. Quote
Stocks That Warrant a Look
Here are some biotech stocks that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat in their upcoming releases.
Horizon Pharma HZNP has an Earnings ESP of +25.00% and a Zacks Rank #3. The company is scheduled to release first-quarter results on May 8. You can see the complete list of today’s Zacks #1 Rank stocks here.
Corbus Pharmaceuticals Holdings, Inc. CRBP has an Earnings ESP of +255.56% and a Zacks Rank #3. The company is scheduled to release first-quarter results on May 9.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year?
Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%.
See Latest Stocks Today >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BioDelivery Sciences International, Inc. (BDSI) : Free Stock Analysis Report
Horizon Pharma Public Limited Company (HZNP) : Free Stock Analysis Report
Corbus Pharmaceuticals Holdings, Inc. (CRBP) : Free Stock Analysis Report
Endo International plc (ENDP) : Free Stock Analysis Report
To read this article on Zacks.com click here.